Article Sidebar
Published:
Apr 14, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of the combined use of docetaxel, cisplatin and apatinib mesylate on serum tumor markers and prognosis in advanced ovarian cancer patients
Abstract
Purpose: To examine the impact of combining docetaxel and cisplatin injections with apatinib mesylate tablets on serum tumor markers and prognosis of advanced ovarian cancer patients.
Methods: A total of 121 advanced ovarian cancer patients admitted to Jiande First People's Hospital, Jiande, China between June 2014 and December 2022 were enrolled in this study. Of these, 59 patients treated solely with docetaxel and cisplatin injections comprised control group while 62 patients who received apatinib mesylate tablets in conjunction with docetaxel and cisplatin injections formed the study group. Serum tumor marker levels, serum vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) levels in peripheral venous blood were evaluated. Furthermore, improvements in ascites, efficacy, incidence of adverse reactions, Karnofsky Performance Status (KPS) scores and quality of life (QoL) scores were recorded. The Kaplan-Meier method was implemented for survival analysis.
Results: After chemotherapy, serum tumor markers (CEA, CA199, CA125, CA153), VEGF and MMP-2 significantly decreased from pre-chemotherapy levels. The study group showed greater reduction than control group (p < 0.05), and also exhibited superior abdominal effusion treatment efficacy and overall effectiveness (p < 0.05). Adverse reactions were rarer in the study group (p < 0.05). The study group's KPS and QoL scores after chemotherapy exceeded those of the control group, with regard to baseline improvement (p < 0.05). Additionally, the study group had a higher 3-year survival rate (p < 0.05).
Conclusion: Although docetaxel and cisplatin injections exhibit significant efficacy in managing advanced ovarian cancer, the adjunctive use of apatinib mesylate tablets augments the efficacy and offers superior safety as well, rendering the combination a potential strategy for improved management of advanced ovarian cancer.
